Previous 10 | Next 10 |
Following up on its initial announcements in January and February , Incyte (NASDAQ: INCY ) reports detailed results from two successful Phase 3 clinical trials, TRuE-AD1 and TRuE-AD2 , evaluating a topical cream formulation of kinase inhibitor ruxolitinib in adolescents and adults wi...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 151 weeks of public selections as part of this ongoing live forward-testing resea...
Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved RUXIENCE™ (rituximab), a monoclonal antibody (mAb) and biosimilar to MabThera ® (rituximab), for the treatment of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheuma...
In a note, Cowen's Ken Cacciatore (Outperform/$8) says Amarin (NASDAQ: AMRN ) could be worth $20 a share based on $10 on Vascepa sales in Europe and $10 upon a successful appeal of the recent patent ruling opening the door for generic competition. More news on: Amarin Corporation plc, Merc...
Pfizer Inc. (NYSE: PFE) today announced the election of Dr. Susan Desmond-Hellmann to its Board of Directors, effective immediately. Dr. Desmond-Hellmann, age 62, was also appointed to the Governance & Sustainability Committee and the Science and Technology Committee of Pfizer’s Bo...
The "Dogs of the Dow" is a strategy for managing the index by buying the ten highest yielding stocks (out of 30). This strategy assumes that the Dow stocks are enough like each other in "maturity" so that a yield advantage will allow one stock to outperform another. This theory works when the ...
Drug repurposing offers an alternative path to drug development by leveraging previous research. The drug development process can be incredibly costly, both in terms of the financial commitment required and the time necessary to advance a drug to approval and production. When setting on a pa...
Three leading biopharmaceutical companies have announced programs enabling employees with medical and laboratory expertise to volunteer their services to local healthcare systems and those hardest hit by COVID-19. Merck & Co., Inc., (NYSE: MRK), Pfizer Inc. (NYSE: PFE), and Eli Lil...
The Senate recently passed a coronavirus relief package as government officials attempt to reduce the impact of measures taken to prevent the spread of coronavirus. Whether or not you agree or disagree with the actions taken, there is no doubt that the $2 trillion spending package is the large...
GlaxoSmithKline (NYSE: GSK) hasn't been spared the market sell-off caused by the COVID-19 pandemic . Year to date, the company's shares are down by 19%, and the healthcare giant is currently hovering near a five-year low. Also, GlaxoSmithKline is trading at just 12.4 times future earni...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in Canada Troilus Gold Corp (TLG) rose 1.4% to $0.7 on volume of 19,342,615 shares Royal Bank of Canada (RY) fell 0.1% to $133.2 on volume of 3,932,729 shares Desjardins RI Developed ex-USA ex-Canada - Low CO2 Index ETF (DRMD) rose 0.0% to $26.72 on volum...
2024-04-18 09:15:00 ET If you had bought $1,000 worth of Pfizer (NYSE: PFE) shares five years ago, how much would that be worth today? The answer will strike you as terrific or terrible: $840. That answer will be terrible if you did buy into Pfizer then as it reflects a loss...
A look at the top 10 most actives in Canada Lucero Energy Corp. (LOU) rose 3.1% to $0.66 on volume of 22,819,193 shares Enbridge Inc. (ENB) rose 0.7% to $45.89 on volume of 15,748,203 shares B2Gold Corp. (BTO) rose 0.3% to $3.67 on volume of 15,231,559 shares BetaPro Natural Gas Leverag...